enGene (ENGN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing non-viral genetic medicines for localized delivery to mucosal tissues and organs, initially targeting non-muscle invasive bladder cancer (NMIBC) with high unmet medical need.

• Proprietary DDX gene delivery platform enables delivery of complex genetic cargos, aiming to expand genetic medicine beyond rare diseases into oncology and other areas.

• Lead product candidate, detalimogene voraplasmid, is designed to promote anti-tumor immune response in bladder urothelium and is in Phase 1/2 clinical trials.

• Focused on bladder-sparing therapies for BCG-unresponsive NMIBC with CIS, with additional research into broader oncology and mucosal disease applications.

Financial performance and metrics

• As of October 31, 2025, cash and cash equivalents were $50.2 million actual and $191.8 million as adjusted for recent financing and loan amendments.

• Shareholders' equity increased from $167.7 million actual to $307.7 million as adjusted, reflecting recent capital raises and loan facility expansion.

• November 2025 public offering raised approximately $149.5 million gross, with $9.4 million in underwriting discounts and offering costs.

• Amended loan agreement with Hercules Capital increased term loan facility to $125 million, with $25 million drawn and up to $100 million available upon milestone achievement.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including research and clinical development, debt repayment, commercialization of detalimogene (if approved), working capital, capital expenditures, and other corporate costs.

• Proceeds may be temporarily invested in short-term, investment-grade instruments or held as cash until used.